Sol-Gel Technologies has finished converting itself from a partnered acne-and-rosacea company into a single-asset rare-disease vehicle. The approved products that once defined the franchise now sit with Mayne Pharma in the United States and with a scatter of territorial licensees elsewhere. What remains is topical patidegib for Gorlin syndrome, a genetic condition that produces relentless basal cell carcinomas and has no approved preventive therapy. The late-November registrational readout is therefore not a catalyst around the edges of the story. It is the story.
The March equity raise retired the going-concern clock that the March annual filing still carried. Cash and securities totaled $49 million at mid-year. That balance is slated to fund operations into early 2028, long enough to absorb a filing cycle if the trial hits and short enough that a miss leaves little room to reinvent the pipeline. The year-ago profit is a comparison artifact from the Mayne intellectual-property sale rather than an operating franchise that disappeared. Underlying royalty revenue is a rounding error next to the research spend that still defines the P&L.
Retention in the registrational study is running well below the company's original dropout assumption, which is the one operational fact that actually changes the prior probability of a clean data set. Last-patient visit is due this month, with top-line results scheduled for late November. The investment question is whether a redesigned single study, after an earlier PellePharm miss, can support keeping full United States economics on an orphan gel the company has valued in the mid-hundreds of millions of peak sales. If the readout fails, the residual royalty stream and a thin expansion program are not a second act.